Analysts Offer Insights on Healthcare Companies: Terns Pharmaceuticals (TERN) and Aurinia Pharmaceuticals (AUPH)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Terns Pharmaceuticals (TERN) and Aurinia Pharmaceuticals (AUPH).
End of Quarter Sale - 50% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Terns Pharmaceuticals (TERN)
Terns Pharmaceuticals received a Hold rating and a $53.00 price target from Truist Financial analyst Srikripa Devarakonda today. The company’s shares closed last Monday at $52.88.
According to TipRanks.com, Devarakonda is a 5-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Terns Pharmaceuticals with a $53.25 average price target, implying a 0.6% upside from current levels. In a report issued on March 24, TD Cowen also downgraded the stock to Hold with a $53.00 price target.
See the top stocks recommended by analysts >>
Aurinia Pharmaceuticals (AUPH)
In a report released today, Stacy Ku from TD Cowen maintained a Buy rating on Aurinia Pharmaceuticals, with a price target of $17.00. The company’s shares closed last Monday at $13.98.
According to TipRanks.com, Ku is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Aurinia Pharmaceuticals with a $16.00 average price target.
Read More on TERN:
Disclaimer & DisclosureReport an Issue
- Terns Pharmaceuticals downgraded to Hold from Buy at Truist
- Terns Parmaceuticles options imply 1.8% move in share price post-earnings
- Netflix initiated, Instacart upgraded: Wall Street’s top analyst calls
- TERN Upcoming Earnings Report: What to Expect?
- Terns Pharmaceuticals downgraded to Equal Weight from Overweight at Barclays
